Lantheus Holdings is considering a possible sale following a takeover proposal from Curium Pharma that puts the company’s value at approximately $7 billion, according to a Bloomberg News report published Friday citing sources with knowledge of the situation.
According to the report, both companies have been engaged in talks regarding a possible transaction that could be finalized within weeks, though sources noted that no definitive agreement has been reached and negotiations may not lead to a completed deal.
The report indicated that Curium received a valuation of roughly $7 billion in the previous year when CapVest Partners, the company’s owner, secured funding for a continuation vehicle for the nuclear medicine business.
Neither Lantheus nor Curium provided immediate responses to requests for comment from Reuters.
The radiopharmaceutical company’s stock declined almost 2% during after-hours trading. The shares have climbed 54.8% year-to-date, bringing the company’s market value to approximately $6.15 billion.
